Grifols | GRFS - Equity Capital And Reserves


Grifols reported EUR6.08B in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Alaunos Therapeutics USD 2.8M 858K Sep/2025
Arca Biopharma USD 486.79M 143.15M Sep/2025
aTyr Pharma USD 80.24M 5.58M Sep/2025
Bio Path USD -7.16M 4.57M Jun/2025
Brainstorm Cell Therapeutics USD -7.69M 1.64M Sep/2025
Capricor Therapeutics USD 83.87M 21.11M Sep/2025
Cara Therapeutics USD 32.93M 41M Jun/2025
Esperion Therapeutics USD -451.36M 17.85M Sep/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Grifols EUR 6.08B 34.72M Sep/2025
Immunic USD 10.5M 23.41M Sep/2025
Infinity Pharmaceuticals USD -37.41M 9.08M Jun/2023
Minerva Neurosciences USD -34.58M 2.47M Sep/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
TherapeuticsMD USD 27.67M 990K Jun/2024